Fundraising Fox
/Companies
Sign in

Respira

Founded 2010 · 10 employees on LinkedIn · 3 known investors

Find your way into Respira

12 people in our graph can introduce you to the Respira team.

Sign up to see every warm intro you have to Respira

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Respira team. We find them
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Respira develops inhaled therapeutic products for pulmonary diseases, including a novel dry-powder inhalation device and lead product candidate RT234 for pulmonary arterial hypertension. The company focuses on creating drug-device combination products using advanced particle engineering and formulation technologies.

BiotechDigital HealthHealthtechMedical Devices

Founders & leadership

JKJohn Kollins
John KollinsChief Executive OfficerJohn Kollins is a biopharma executive with over 30 years of experience in leadership roles at public and private companies developing therapeutic products across cardiopulmonary, CNS, oncology, autoimmune, and ophthalmology domains. He currently serves as CEO of Respira, which develops inhaled drug-device combination products for pulmonary diseases.

Investors · 3

Samsara BioCapitallisted by Samsara BioCapitalMenlo Park

How we know: Samsara BioCapital's portfolio page · Not right? Tell us

Zentynel Frontier InvestmentsreportedSantiago

How we know: copdnewstoday.com · Not right? Tell us

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 3

FreespiraFreespira develops an FDA-indicated medical device combined with clinical support for treating PTSD and panic disorder symptoms at home over 28 days. The solution serves health plans, healthcare providers, and self-insured employers seeking to improve patient outcomes and optimize healthcare resource utilization.
Spyre TherapeuticsSpyre develops and commercializes treatments for a broad range of diseases focused on improving patient outcomes.
AlumniAstraZeneca develops and markets pharmaceutical products, vaccines, and biologics across oncology, cardiovascular disease, respiratory and immunology, and rare disease areas, serving patients and healthcare providers globally.

Companies working in the same space as Respira.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2019$225K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Respira do?
Respira develops inhaled therapeutic products for pulmonary diseases, including a novel dry-powder inhalation device and lead product candidate RT234 for pulmonary arterial hypertension. The company focuses on creating drug-device combination products using advanced particle engineering and formulation technologies.
Who are Respira's investors?
Respira's investors include Cottonwood Technology Fund, Samsara BioCapital, Zentynel Frontier Investments.